A detailed history of Rhumbline Advisers transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 77,300 shares of DAWN stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
77,300
Previous 85,438 9.53%
Holding current value
$1.06 Million
Previous $1.18 Million 8.58%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$12.72 - $16.03 $103,515 - $130,452
-8,138 Reduced 9.53%
77,300 $1.08 Million
Q2 2024

Aug 01, 2024

SELL
$12.03 - $17.69 $51,596 - $75,872
-4,289 Reduced 4.78%
85,438 $1.18 Million
Q1 2024

May 09, 2024

BUY
$13.56 - $17.46 $31,093 - $40,035
2,293 Added 2.62%
89,727 $1.48 Million
Q4 2023

Feb 08, 2024

SELL
$9.68 - $15.37 $17,123 - $27,189
-1,769 Reduced 1.98%
87,434 $1.28 Million
Q3 2023

Nov 09, 2023

BUY
$11.22 - $14.86 $257,409 - $340,918
22,942 Added 34.62%
89,203 $1.09 Million
Q2 2023

Aug 08, 2023

BUY
$11.74 - $14.47 $261,391 - $322,174
22,265 Added 50.61%
66,261 $791,000
Q1 2023

May 11, 2023

BUY
$12.75 - $23.41 $13,298 - $24,416
1,043 Added 2.43%
43,996 $588,000
Q4 2022

Feb 14, 2023

BUY
$18.77 - $22.0 $13,345 - $15,642
711 Added 1.68%
42,953 $924,000
Q3 2022

Nov 10, 2022

BUY
$16.44 - $26.57 $136,254 - $220,212
8,288 Added 24.41%
42,242 $846,000
Q2 2022

Aug 11, 2022

BUY
$5.72 - $17.9 $83,203 - $260,373
14,546 Added 74.95%
33,954 $608,000
Q1 2022

May 12, 2022

BUY
$9.12 - $17.47 $177,000 - $339,057
19,408 New
19,408 $193,000

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $1.01B
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.